Home › Research › Costs and economics
Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060
Mudrazija S, Aranda MP, Gaskin DJ, Monroe S, Richard P. JAMA Network Open, 2025-06-05
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This modeling study projects that the financial toll of Alzheimer's and related dementias will grow very unevenly by race and ethnicity in the US. While white families currently bear the largest dollar burden overall, the combined burden on Black and Latino families is projected to grow much faster, driven largely by unpaid family caregiving, and Latino caregivers already lose a much larger share of household income to caregiving than white or Black caregivers do.
What this study adds
Evidence grade: Moderate
The record lists 31,028 participants. This modeling study projects that the financial toll of Alzheimer's and related dementias will grow very unevenly by race and ethnicity in the US, with the combined burden on Black and Latino families projected to grow much faster than that on white families. Its stated limit: Long-horizon (40-year) projections rely on multiple linked survey data sources and assumptions about future demographic, wage, and cost trends that carry substantial uncertainty.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mudrazija, S., Aranda, M. P., Gaskin, D. J., Monroe, S., & Richard, P. (2025). Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060. JAMA Network Open.
Vancouver
Mudrazija S, Aranda MP, Gaskin DJ, Monroe S, Richard P. Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060. JAMA Network Open. 2025. PMID: 40471578.
BibTeX
@article{mudrazija2025-89faa596,
author = {Mudrazija, S. and Aranda, M. P. and Gaskin, D. J. and Monroe, S. and Richard, P.},
title = {{Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060}},
journal = {JAMA Network Open},
year = {2025},
pmid = {40471578}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Total US economic burden of ADRD projected to rise from $344 billion (2020) to over $3 trillion (2060)
- Combined African American and Latino economic burden projected to rise from $113 billion (2020) to $1.7 trillion (2060)
- Latino family caregivers' forgone wages represented 15.7% of household income in 2020, versus 9.4% for African American and 8.1% for white caregivers
- Unpaid caregiving value was the largest and fastest-growing cost component across all racial/ethnic groups
Why it matters
This modeling study projects that the financial toll of Alzheimer's and related dementias will grow very unevenly by race and ethnicity in the US, with the combined burden on Black and Latino families projected to grow much faster than that on white families. Latino caregivers already lose a much larger share of household income to caregiving than white or Black caregivers do.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designmodelling
- Participants31,028
- Effect sizeTotal US ADRD economic burden projected to rise from $344 billion (2020) to over $3 trillion (2060); African American and Latino populations' combined burden projected to rise from $113 billion (2020, one-third of the total) to $1.7 trillion (2060), driven mainly by unpaid caregiving costs
- Evidence strengthModerate
Limitations
Long-horizon (40-year) projections rely on multiple linked survey data sources and assumptions about future demographic, wage, and cost trends that carry substantial uncertainty.
How this study scored 61/100
Published in a leading specialty journal, and it is a computer model rather than new measurements. Scored zero for randomized / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 38 of the 62 points we could judge it on, which is 61 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Network Open) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 3 / 12 | A computer model rather than new measurements |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 31,028 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 38 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 38 of the 62 points we could judge it on is 61 out of 100. |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Costs and economics from nearby years
Also in Costs and economics
21 studies in the library are filed under Costs and economics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Costs and economics hub.